Skip to main content
Clinical Trials/NCT06289842
NCT06289842
Recruiting
N/A

Efficacy of Accelerated Theta Burst Stimulation for Treatment of Suicidality in Patients With Unipolar and Bipolar Depression

Zagazig University1 site in 1 country34 target enrollmentFebruary 1, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Suicide and Depression
Sponsor
Zagazig University
Enrollment
34
Locations
1
Primary Endpoint
Change in suicidal ideation and behaviors as measured by Columbia Suicide Severity Rating Scale (C-SSRS)
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The objective of this study is to investigate efficacy of accelerated theta burst stimulation (TBS) in suicidal reduction in patients with unipolar and bipolar depression

Detailed Description

Introduction: Depression is the leading cause of disability worldwide and is associated with increased suicide risk, morbidity and mortality.(Sousa et al .,2022). In severe cases, depression can result in suicide and approximately 800,000 suicides occur each year (Lepine et al.,2011). Rates of completed suicide are also high, varying from 10 to 19% (Goodwin et al., 1990). Lifetime rates of attempted suicide in bipolar depression range (26-29%) and (14-16%) in unipolar depression disorder (Chen et al., 1996). The general recommendation to reduce suicide risk is the effective treatment of the underlying depressive disorder, with medications and psychosocial interventions (Jacobs et al., 2010). However, there exist several difficulties. Neither antidepressants nor psychotherapy work fast enough for reduction of suicidal ideation. Beside pharmacotherapy and psychotherapy brain stimulation methods have gained increasing relevance in the treatment of depression during the last decades (Baeken et al.,2019). Repetitive transcranial magnetic stimulation (rTMS) therapy is a noninvasive neurostimulation treatment that has been adopted as a first-line treatment for pharmacotherapy-resistant major depressive disorder (MDD) (Milev et al., 2016). Despite this growing evidence base supporting (iTBS) in the treatment of MDD, evidence for its efficacy in the treatment of suicidality as a primary outcome in both unipolar and bipolar depressive patients is still lacking. Hypothesis We assume that accelerated TBS is effective in treatment of suicidality as well as depressive symptoms in both unipolar and bipolar patients. Aim This study aims to reduce morbidity and mortality of unipolar and bipolar depressive patients and to improve overall functioning. Objectives 1. To investigate efficacy of accelerated TBS in suicidal reduction as primary outcome in patients with unipolar and bipolar depression. 2. To compare efficacy of accelerated TBS in reduction of severity of depressive symptoms in unipolar and bipolar disorder as well as response and remission rates. 3. To investigate association between the reduction of suicidality and the reduction of depressive symptoms

Registry
clinicaltrials.gov
Start Date
February 1, 2024
End Date
January 2026
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Medhat Bassiony

Professor of Psychiatry

Zagazig University

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of Major depressive episode as a part of MDD or bipolar (I or II) disorder and confirmed by Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID-I). (First \& Gibbon.,2004 ).
  • Meeting the severe depression cutoff for MADRS (\>/=35) at baseline visit.
  • Meeting the severe depression cutoff for BDI-II (\>/=30) at baseline visit.
  • Presence of suicidal ideation and/or behavior (confirmed with Columbia Scale for the Rating of Suicide Severity (C-SSRS)
  • Adults (Age 19 years or older )
  • Right handedness
  • Both genders
  • Able to provide informed consent to participate in the study
  • Participants were required to have been taking a stable pharmacological regimen for 2 weeks before screening.
  • Pass the TMS adult safety screening (TASS) questionnaire

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Change in suicidal ideation and behaviors as measured by Columbia Suicide Severity Rating Scale (C-SSRS)

Time Frame: Assessed at baseline (day 0) , post-inpatient treatment completion (day 5) , 1 month ,3 month , 6 month, 9 month and 12 month

The SI severity scale is composed of five yes=no questions of increasingly severe suicidal thoughts: a wish to be dead (1), non-specific suicidal thoughts (2), suicidal thoughts with a method (3), suicidal intent without specific plan (4), and suicidal intent with specific plan (5). This scale was scored from 0 to 5 according to the most severe suicidal ideation endorsed. Higher scores mean worse outcome. Suicidal behaviors were assessed dichotomously (yes=no) and include actual suicide attempts, interrupted suicide attempts, aborted suicide attempts, other preparatory acts (e.g., collecting pills, writing suicide note), and non-suicidal self-injury (NSSI).

Secondary Outcomes

  • Change from baseline Montgomery-Åsberg Depression Rating Scale (MADRS) Score(Assessed at baseline (day 0) , post-inpatient treatment completion (day 5) , 1 month ,3 month , 6 month ,9 months and 12 month)

Study Sites (1)

Loading locations...

Similar Trials